Abstract
Background
Somatic point mutations in the fibroblast growth factor receptor 3 (FGFR3) gene have been identified in certain types of urological cancers, especially urothelial carcinoma of the bladder and the renal pelvis, and could be correlated with a favourable outcome. However, comprehensive data on the FGFR3 mutation status in renal cell carcinoma (RCC) are still missing.
Methods
In order to investigate a possible role for FGFR3 mutations in renal cell carcinogenesis, we performed a sequence-based mutational analysis of FGFR3 in 238 primary RCC. The cohort obtained the common RCC subtypes including 101 clear cell, 50 papillary and 68 chromophobe RCC specimens. The analysed regions encompassed all FGFR3 point mutations previously described in epithelial tumours and other noncutaneous epithelial malignancies.
Results
No mutations were detected in any renal tumour type examined, and all cases showed wild-type sequence.
Conclusion
Our results argue against an involvement of mutational activation of FGFR3 in the development of RCC. A recently described cystic renal dysplasia in a patient with thanatophoric dysplasia type 1 due to a germ line FGFR3 mutation might portend to an involvement of mutational FGFR3 activation in renal cyst formation, but this speculation needs further evaluation.
This is a preview of subscription content, log in via an institution to check access.
References
Bates M (2007) Role of fibroblast growth factor receptor signaling in kidney development. Pediatr Nephrol 22(3):343–349
Cenni E, Perut F, Granchi D, Avnet S, Amato I, Brandi ML, Giunti A et al (2007) Inhibition of angiogenesis via FGF-2 blockage in primitive and bone metastatic renal cell carcinoma. Anticancer Res 27:315–320
Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED (2007) Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 75(9):831–842
Cronauer MV, Schulz WA, Seifert HH, Ackermann R, Burchardt M (2003) Fibroblast growth factors and their receptors in urological cancers: basic research and clinical implications. Eur Urol 43(3):309–319
Fujimoto K, Ichimori Y, Yamaguchi H et al (1995) Basic fibroblast growth factor as a candidate tumor marker for renal cell carcinoma. Jpn J Cancer Res 86:182–186
Greene FL, Page DL, Fleming ID, Fritz AG, Batch CM, Haller DG, Morrow M (2002) American Joint Committee on Cancer (AJCC) Cancer staging manual. Springer, New York
Grignon DJ, Eble JN, Bonsib SM, Moch H, Delahunt B, Störkel S, Pavlovich CP et al (2004) Tumours of the kidney. In: Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon, pp 10–34
Hafner C, van Oers JM, Vogt T, Landthaler M, Stoehr R, Blaszyk H, Hofstaedter F, Zwarthoff EC, Hartmann A (2006) Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. J Clin Invest 116:2201–2207
Hajj P, Ferlicot S, Massoud W, Awad A, Hammoudi Y, Charpentier B, Durrbach A, Droupy S, Benoît G (2009) Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology 74:631–634
Myoken Y, Myoken Y, Okamoto T, Kan M, McKeehan WL, Sato JD, Takada K (1996) Expression of fibroblast growth factor-1 (FGF-1), FGF-2 and FGF receptor-1 in a human salivary-gland adenocarcinoma cell line: evidence of autocrine growth. Int J Cancer 65:650–657
Prontera P, Sensi A, Pilu G, Baldi M, Baffico M, Bonasoni R, Calzolari E (2006) FGFR3 mutation in thanatophoric dysplasia type 1 with bilateral cystic renal dysplasia: coincidence or a new association? Genet Couns 17(4):407–412
Qiao J, Bush KT, Steer DL, Stuart RO, Sakurai H, Wachsman W, Nigam SK (2001) Multiple fibroblast growth factors support growth of the ureteric bud but have different effects on branching morphogenesis. Mech Dev 109(2):123–135
Rossini M, Cheunsuchon B, Donnert E, Ma LJ, Thomas JW, Neilson EG, Fogo AB (2005) Immunolocalization of fibroblast growth factor-1 (FGF-1), its receptor (FGFR-1), and fibroblast-specific-protein-1 (FSP-1) in inflammatory renal disease. Kidney Int 68:2621–2628
Sibley K, Stern P, Knowles MA (2001) Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours. Oncogene 20(32):4416–4418
Sobin LH, Wittekind C (2002) TNM Classification of Malignant Tumors. Wiley, New York, Weinheim
Song X, Di Giovanni V, He N, Wang K, Ingram A, Rosenblum ND, Pei Y (2009) Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Hum Mol Genet 18(13):2328–2343
Thomas RK, Baker AC, Debiasi RM, Meyerson M, Garraway LA et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39(3):347–351
van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC (2005) A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11:7743–7748
Acknowledgments
The authors thank Anne Pietryga-Krieger, Rudolf Jung and Nina Niessl for excellent assistance.
Conflict of interest
There is no financial support or conflict of interest involved in this contribution.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stoehr, C.G., Stoehr, R., Hartmann, A. et al. Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma. J Cancer Res Clin Oncol 138, 359–361 (2012). https://doi.org/10.1007/s00432-011-1130-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-011-1130-x